SNDL Inc. (SNDL) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SNDL Inc. (SNDL) advanced +0.78% to $1.30, trading at 14% of its 52-week range ($1.13 – $2.34). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
SNDL came into this Q3 2026 report as a low P/S cannabis and liquor hybrid that many investors still view as a turnaround story. The stock barely flinched after the release, slipping about 0.8% to $1.29, yet the headline
SNDL's Q3 sales beat expectations, but margin pressure and persistent cannabis weakness cloud its recovery. Can buybacks and U.S. expansion turn the tide?
SNDL Inc. posted record free cash flow but faces near-term earnings pressure from restructuring and product cuts. Click for this earnings update of SNDL stock.
SNDL disclosed layoffs alongside its fiscal Q3 earnings. But does that warrant buying SNDL stock today? Let’s find out!
Record free cash flow and profitability offset revenue decline.
Moby summary of SNDL Inc.'s Q3 2026 earnings call
SNDL (NASDAQ:SNDL) reported record quarterly free cash flow and a return to positive adjusted operating income in the third quarter of 2026, while recording a substantial goodwill impairment and continuing to address und
SNDL Inc. (SNDL) Q3 2026 Earnings Call October 27, 2026 10:00 AM EDTCompany ParticipantsZachary George - CEO & DirectorAlberto Paredero-Quiros - Chief...
The Company Makes Significant Strategic Investments While Improving Underlying Financial Performance and Generating Record Quarterly Free Cash Flow of $20 MillionEDMONTON, Alberta, Oct. 27, 2026 (GLOBE NEWSWIRE) -- SNDL
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SNDL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SNDL. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, SNDL Inc. (SNDL) ranks #192 by composite RQD confidence (61/100, grade C-) and #515 by equity capitalization ($316.3M). Within this direct 5-issuer industry benchmark cohort, USNA leads on earnings valuation at 24.6x trailing P/E, while USNA leads on capital efficiency and profitability with 7.9% ROIC and 78.3% gross margin. SNDL currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SNDL
ACTIVE
SNDL Inc. | C- | 61/100 | — | — | — | +0.78% | $316.3M | Benchmark Subject |
| CGC Canopy Growth Corporation | D | 51/100 | — | — | — | +0.46% | $285.6M | /cgc-vs-sndl → |
| OBIO Orchestra BioMed Holdings Inc. | E | 28/100 | — | 96.0% | -35.0% | +1.67% | $366.0M | /obio-vs-sndl → |
| USNA USANA Health Sciences Inc. | C- | 61/100 | 24.6x | 78.3% | 7.9% | -1.91% | $265.0M | /usna-vs-sndl → |
| TLRY Tilray Brands Inc. | E | 32/100 | — | 28.4% | -3.9% | -1.86% | $390.2M | /tlry-vs-sndl → |
SNDL Inc. (SNDL) operates in Medicinal Chemicals and Botanical Products (Health Care) with an equity capitalization of $316.3M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-01, SNDL Inc. (NASDAQ: SNDL) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $1.30 (+0.78% 1D, market cap $316.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SNDL ranks #192 in composite RQD confidence.
Within the Health Care sector (Medicinal Chemicals and Botanical Products), SNDL carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CGC (Canopy Growth Corporation) holds a D grade (51/100 RQD, P/E N/A, ROIC —, cap $285.6M) and OBIO (Orchestra BioMed Holdings Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $366.0M). Among the 5-stock peer group, USNA leads on earnings multiple (24.6x) while USNA leads on capital efficiency (7.9% ROIC).
For SNDL Inc. (SNDL), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #192 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
SNDL last traded at $1.30 (+0.78% on volume of 1,082,601 shares), positioning the stock -1.52% below its 50-day simple moving average ($1.32) and -6.47% below its 200-day simple moving average ($1.39). Across its 52-week range of $1.13 to $2.34, SNDL sits at the 14.0% percentile with a 14-day RSI of 43.6 (NEUTRAL RANGE) and an implied next-earnings move of ±8.5% ($1.19 to $1.41).
Why SNDL Stock advanced +0.78% Today — RQD Quant Desk Flash. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.